Needham Releases a Hold Rating on Hill-Rom (HRC)

Needham analyst Michael Matson assigned a Hold rating to Hill-Rom (HRCResearch Report) today. The company’s shares closed last Wednesday at $134.49.

According to, Matson is a 5-star analyst with an average return of 16.9% and a 68.9% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.

Currently, the analyst consensus on Hill-Rom is a Strong Buy with an average price target of $127.00.

See today’s analyst top recommended stocks >>

Based on Hill-Rom’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $762 million and net profit of $87.1 million. In comparison, last year the company earned revenue of $723 million and had a net profit of $46.9 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Hill-Rom Holdings, Inc. is a medical technology company, which focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following business segments: Patient Support System, Front Line Care, and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility, and clinical workflow solutions. The Front Line Care segment offers respiratory care products; and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products, and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.